Gisele Lopes Cavalcante, Lívia Pimenta Bonifacio, Jéssica Maria Sanches-Lopes, Fernanda Guioti Puga, Felipe Santos de Carvalho, Fernando Bellissimo-Rodrigues, Jose Eduardo Tanus-Santos
COVID-19 is a devastating disease and imbalanced matrix metalloproteinase (MMP) activity may contribute to its pathophysiology. This exploratory study examined whether increased circulating concentrations of MMP-2 and MMP-9, and their endogenous inhibitors, the tissue inhibitors of MMP (TIMP)-1, TIMP-2, TIMP-3 and TIMP-4 are persistently found in patients 2 weeks after their recovery from severe or critical COVID-19 as compared with those in healthy controls. Subjects who had severe (n = 26) or critical (n = 25) PCR-confirmed COVID-19 and healthy controls (n = 21) had blood samples drawn 2 weeks after recovery and serum MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3 and TIMP-4 were determined using two Human Luminex® Discovery Assays...
March 11, 2024: Basic & Clinical Pharmacology & Toxicology